Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Vanda Pharmaceuticals Inc.    VNDA

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/09/2018 01/10/2018 01/11/2018 01/12/2018 01/16/2018 Date
14.2(c) 14.05(c) 14.35(c) 14.5(c) 14.2(c) Last
625 779 878 655 474 062 231 018 598 641 Volume
-0.35% -1.06% +2.14% +1.05% -2.07% Change
More quotes
Financials ($)
Sales 2017 164 M
EBIT 2017 -22,7 M
Net income 2017 -16,3 M
Debt 2017 -
Yield 2017 -
Sales 2018 191 M
EBIT 2018 -13,5 M
Net income 2018 -11,5 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 3,97x
Capi. / Sales2018 3,41x
Capitalization 651 M
More Financials
Company
Vanda Pharmaceuticals, Inc. is a global biopharmaceutical company, which focuses on the development and commercialization of innovative therapies to improve the lives of patients.It intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian... 
More about the company
Surperformance© ratings of Vanda Pharmaceuticals Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on VANDA PHARMACEUTICALS INC.
01/11 VANDA PHARMACEUTICALS : Patent Issued for Treatment of Circadian Rhythm Disorder..
01/08 VANDA PHARMACEUTICALS INC. : Results of Operations and Financial Condition, Regu..
01/07 VANDA PHARMACEUTICALS : Reports Preliminary Fourth Quarter and Full Year 2017 Re..
2017 VANDA PHARMACEUTICALS : U.S. Patents Awarded to Inventors in Kansas (Dec. 28)
2017 VANDA PHARMACEUTICALS : New Vanda Pharmaceuticals’ Abstracts Suggest Circa..
2017 VANDA PHARMACEUTICALS : Announces Participation at November 2017 Investor Confer..
2017 VANDA PHARMACEUTICALS : Announces Participation at November 2017 Investor Confer..
2017 VANDA PHARMACEUTICALS : Receives Negative Opinion for Marketing Authorization fr..
2017 VANDA PHARMACEUTICALS : Receives Negative Opinion for Marketing Authorization fr..
2017 VANDA PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condit..
More news
Sector news : Bio Therapeutic Drugs
01/12 Drugmakers see a pricing blueprint in an $850,000 gene therapy
01/12 SPARK'S PRICE FOR LUXTURNA BLINDNESS : Icer
01/08 $11 billion biotech binge fuels forecasts of 2018 M&A surge
01/08 SANOFI : and Regeneron boost investment in cancer drug cemiplimab
01/07 ALNYLAM PHARMACEUTICALS : Sanofi Restructure RNAi Rare-Disease Alliance -- Updat..
More sector news : Bio Therapeutic Drugs
Latest Tweets
01/14Jim Kelly's 2014 prayers were answered last night when he was able to walk hi..
6
01/14Prayers answered: Hall of Fame QB Jim Kelly walks daughter down aisle
5
01/132014 prayer answered: Jim Kelly to walk daughter down aisle Saturday  
01/13Congratulations JK-12! Jim Kelly's prayers are answered with his daughter's w..
2
01/13Football Hall of Famer and former Bills QB Jim Kelly will walk his daughter d..
11
More tweets
Qtime:95
News from SeekingAlpha
01/10 YOUR DAILY PHARMA SCOOP : Aradigm Sees Sell-Off Ahead Of Ad Com, Editas Provides..
01/06 YOUR DAILY PHARMA SCOOP : Lipocine Ahead Of Ad Com, Ohr's MAKO Study Fails, Zafg..
2017 Vanda strikes out in appeal of thumbs down from European advisory group on Fa..
2017 Vanda Pharmaceuticals' (VNDA) CEO Mihael Polymeropoulos on Q3 2017 Results - ..
2017 Vanda Pharmaceuticals beats by $0.08, misses on revenue
Chart VANDA PHARMACEUTICALS INC.
Duration : Period :
Vanda Pharmaceuticals Inc. Technical Analysis Chart | VNDA | US9216591084 | 4-Traders
Technical analysis trends VANDA PHARMACEUTICALS INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 20,4 $
Spread / Average Target 41%
EPS Revisions
Managers
NameTitle
Mihael Hristos Polymeropoulos President, Chief Executive Officer & Director
H. Thomas Watkins Chairman
James Patrick Kelly Chief Financial Officer, Treasurer & Senior VP
Vincent J. Milano Independent Director
Michael F. Cola Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
VANDA PHARMACEUTICALS INC.-4.61%651
GILEAD SCIENCES10.30%103 247
VERTEX PHARMACEUTICALS5.39%40 060
REGENERON PHARMACEUTICALS-2.39%39 566
GENMAB11.27%11 475
EXELIXIS, INC.-0.07%8 899